Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Health Care Industry Segment
The analysis of genetic variation and function plays an increasingly important role in molecular biology, By empowering genomic and proteomic analysis, Arrayit Corporation’s tools and trade secrets advance disease research, drug development, and the creation of molecular diagnostic tests. In addition to developing all types of microarray-based solutions for life science, applied science, and consumer markets, Arrayit is facilitating the transition to the clinic, by supporting and carrying out clinical trials to gather data for regulatory submissions in the US and globally, and establishing infrastructure to offer products designed and manufactured in compliance with global quality standards for medical devices.
As personalized medicine progresses, it has become apparent that millions of people will need to be tested for various diseases or traits in order to identify whether or not a disease is present, or to determine compatibility with specific drug treatments. However, testing millions of patient samples, one at a time, would overwhelm laboratory testing facilities and be cost prohibitive. To solve this problem, Dr. Mark Schena developed and patented a method to place up to 100,000 individual patient samples on a single microarray substrate slide. That slide is then immersed in a solution that contains the known markers for a specific disease, such as congenital hearing loss, Parkinson’s Disease, Alzheimer’s Disease, etc. The results are as easy as reading a traffic signal. Should any one of those 100,000 patient samples contain the marker for the disease being tested, a red spot appears, and if not, a green spot appears. This procedure can also identify carriers as yellow spots. Because of the sophistication of this patented invention, one lab could test hundreds of thousands of patient samples a day after receiving a sample of DNA from each patient. It is the only method available to the industry that can accomplish this. Dr. Schena’s multi-patient genotyping procedure is protected by the following patents:
US Patent 6,913,879
Australia 2002218740
Europe 1343911
Korea 10-0756015
New Zealand 523560
Singapore 94899
Taiwan I280282
Israel 153848
Other worldwide patents pending
So why are you still here?
Thanks Mike. Always appreciate your due diligence
You're right, Mykkus. Totally my fault. They feed off negativity not facts.
Calm? Let's look at our history of posts and see who's not calm. Ridiculous
Hey genius, it's relevant because it says that I'm looking at the larger overall chart performance, not the short term up and down.
Oh no! What should I do? Should I sell then? I'm only up 800% ??
Per Mike's DD, the Q3 financials for 2018 are due by Nov 9. I wonder if we will receive all the 10-Ks for prior years and the 10-Qs for the 1st, 2nd, and 3rd quarter of this year to be truly current. We are very close guys. Don't sell and continue to load on the dips if you can. IMO you won't see anything lower than a dime in a few weeks. GLTA
wieder falsch
I'm not worried about these day to day fluctuations in share price. I believe these trading days are irrelevant for what's to come soon. IMO the focal point is becoming current with financials, removal of CE, and as a huge bonus - FDA approvals. Everything else outside of these events during these trading days don't bother me at all. Like I said from before, I don't have as much riding on this as others - my holding doesn't impact any retirement or savings funds. I only see upside from here
Cool thanks Mike
My guess(es) for tomorrows PR:
- Albertsons will be named as retail chain partner for in-store finger prick blood testing
- USDA order has been shipped
- 10-Ks have been filed and will be updated by EDGAR soon
- Some obscure update that has nothing to do with financials lol
Just hitting refresh here every hour or so lol
https://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=aryc&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
More investors will come but need to have that CE removed first - which can only happen after this quiet period and 10-Ks are all filed
What impresses me with the tweets are the direct links they provide about the customers who are buying their products. Not a single school, research lab, health organization, etc has denied the sale. AND these tweets aren't even all the sales they are doing daily. IMO the financials will be very positive. Patience here will pay off big time
Thanks Sloan, I agree with their plan but think that it should have been done long ago. Oh well. Here's to the future
HAHA That "PR means Public Relations" comment cracked me up today. Hope it comes Monday!
No problem, Ace. It's really nice of Mark to have responded to every single email. I simply emailed him today thanking him for being so responsive to me and asked if it was Arrayit or RRBB's decision to do the quiet period. His "we" probably implies both parties agreed on it. Have a great weekend!
Late update from Mark today:
Dear Cary, Thanks for your ongoing support. We are using a "quiet period" between now and when the 10-Ks are filed to ensure that all shareholders receive identical public information. This protects the interests of our shareholders by making sure we arefully complaint with regulations governing public companies. We look forward to your ongoing participation. Thanks and have a nice weekend. Mark
http://arrayit.com/index.html
As much as I am excited about the future of this company, I agree with this statement. IMO they should have a board of directors that would hold Mark and Rene accountable for their actions as a public company and its responsibilities towards its shareholders. I don't blame Mark at all for making a lot of statements that were too "hopeful" about target dates - he does take a lot of pride in Arrayit and his intentions to try to answer every email correspondence says a lot about how genuine he is. Rene, on the other hand, has a lot to work on being the CEO of the company. Even if they didn't hit their summer 2018 goal of financials - a letter to shareholders about why and what the next steps are would have been nice from her. Having these basic communications from the CEO is NOT too much to ask for as a shareholder. She should know this as the CEO of a publicly traded company.
Thanks for the email update, Starlight84!
multiple emails
I'm happy for all the investors here both longs and new. Like many have said, this is just the beginning. This PPS is still a small fraction of what it will be end of year and next year IMO
Holy crap! I've been in meetings too and came back to this chart. I thought news broke while I was gone lol
Reiterating Rene's PR post:
Arrayit
-recently completed an allergy testing pilot program for a top retail chain
-established a nationwide network of 1,700 allergy sales professionals
-met with top officials at the FDA regarding approval of a major product line
-reported the sale of clinical instrumentation to the FDA
-signed allergy testing contracts with a consortium of 178 medical clinics
-received approval for in-store promotions by a major retailer
-announced allergy testing partnerships with major allergy therapeutics providers and was approved for direct Medicare billing by CMS
-The clinical instrumentation and software shipped to the FDA, which regulates consumer products exceeding $1,000,000,000,000 ($1 trillion) in annual revenues, allows hands-on use by FDA scientists.
Sorry you are correct. IMO... SEC has the audit results and we are in the quiet period of waiting for it to be filed as valid. IMO IMO IMO
Catch up on your DD before posting. SEC has the audits and financials are pending any day now. CE will be gone soon
Yes indeed. Real company. Real products. Real Science. Real government contracts. Awaiting SEC reviews. FDA pending. More deals to come.
No one can find a SINGLE company, school, or organization in their tweets that came forward to contradict the partnership or sale including the US Government. Also, they're buying the rest of the building for expansion. Easiest DD is to have a site visit. That PPS decimal will be jumping to the right soon. Get in, stay in, or stop complaining and get out. Simple as that
IMO Probably not until Monday or Tuesday. I think it'll float around the .07s and upper .06s for now. But you never know with MMs and manipulators. As long as the longs keep holding
Cool!! Thanks Travis
Thanks for sharing Jhols!
Me too! Hopefully follows the recent trend of FDA updates!
Ah good point, Mike. I forgot about that period of time. I bought right after all the dilution hoping for this turn around we're seeing
Great post, techmover! My sentiments exactly. I'm now just excited anticipating the FDA approval
Oh I don't doubt one bit that they are paid to do so. What would be their end game or gain to post negative things unless they have an incentive for this stock to fail? As long as the ignore option is being used, we can focus on the facts and not let them be such a distraction. Their tactics are so ridiculous and obvious
Thanks for reiterating:
The “quiet period” refers to our completed audit and financial filings. Our next financial announcement will be when the 10-Ks are filed
Majority of complainers probably didn't buy in years or months ago so they got in super late and are down from the .08s or even .11 so they aren't too thrilled about losing money. Also we already know about the certain group of usual suspects who have nothing better to do as well
10-Ks (plural)...thanks for sharing Starlight
One of the best posts I've seen. Made me laugh my ass off too
Boom!!! Thanks for the update, J!!!!